uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.1139 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of bronchial neoplasm? | Trametinib has not been approved by the FDA as a treatment for bronchial neoplasm, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bronchial neoplasm%" OR LOWER(efo_term) LIKE "%bronchial neoplasm%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928687', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928807', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928847', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928887', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928967', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929007', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929047', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929127', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929167', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929207', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929247', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929327', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929367', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929407', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929447', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929487', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929527', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929567', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929607', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929647', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929687', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929767', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929807', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929847', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929887', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929927', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930007', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930047', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930087', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930127', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930167', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930207', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930247', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930287', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930327', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930367', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930407', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930447', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930487', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930527', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930567', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930607', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930647', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930687', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930727', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930767', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930807', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930847', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930887', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930927', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930967', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931047', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931087', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931127', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931167', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931207', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931247', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931327', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931367', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931407', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931447', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931487', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931527', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931567', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931607', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931647', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931687', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931727', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931767', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931807', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931847', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931887', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931927', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931967', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932007', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932047', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932087', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932127', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932167', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932207', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932247', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932287', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932327', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932367', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932407', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932447', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931007', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929727', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929087', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928767', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928607', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928527', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928487', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931287', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929967', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929287', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928927', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928727', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928647', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928567', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.457 | Q34 | What are the names of the genes that are targeted by the drug Phenylephrine Hydrochloride in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Phenylephrine Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%phenylephrine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%phenylephrine hydrochloride%" OR LOWER(syns_list) LIKE "%phenylephrine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416699', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416627', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416609', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416663', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_416681', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416645', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1691 | Q34 | What are the names of the genes that are targeted by the drug Goserelin Acetate in the treatment of carcinoma? | In the context of carcinoma, the drug Goserelin Acetate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%carcinoma%" OR LOWER(efo_term) LIKE "%carcinoma%") AND (LOWER(drugName) LIKE "%goserelin acetate%" OR LOWER(tradeNames_list) LIKE "%goserelin acetate%" OR LOWER(syns_list) LIKE "%goserelin acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096842', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096855', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096841', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096870', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096856', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096828', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096869', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096827', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096930', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096824', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096884', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096852', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096915', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096898', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096896', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096881', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096918', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096837', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096851', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096913', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096932', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096935', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096901', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096879', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096823', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096838', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096865', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096866', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096875', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Lobular', 'efo_term': 'invasive lobular carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096846', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096926', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Lobular', 'efo_term': 'invasive lobular carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096860', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096818', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096892', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Lobular', 'efo_term': 'invasive lobular carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096909', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Lobular', 'efo_term': 'invasive lobular carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096832', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096817', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096859', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096831', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096845', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1499 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of fungal infectious disease? | In the context of fungal infectious disease, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fungal infectious disease%" OR LOWER(efo_term) LIKE "%fungal infectious disease%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057600', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058083', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058244', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058405', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058727', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058888', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059049', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059371', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059532', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059693', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059854', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060176', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060337', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060498', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060659', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060820', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060981', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061142', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061303', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061464', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061625', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061947', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062108', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062269', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062430', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062591', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062913', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063074', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063235', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063396', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063557', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063718', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063879', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064040', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064201', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064362', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064523', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064684', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064845', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065006', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065167', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065328', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065489', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065650', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065811', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065972', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066133', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066294', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066455', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066616', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066777', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067099', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067260', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067421', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067582', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067743', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067904', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068226', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068387', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068548', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068709', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068870', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069031', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069192', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069353', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069514', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069675', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069836', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069997', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070158', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070319', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070480', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070641', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070802', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070963', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071124', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071285', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071446', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071607', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071768', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071929', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072090', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072251', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072412', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066938', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061786', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059210', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057922', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057278', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056956', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056795', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068065', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062752', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060015', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058566', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057761', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057439', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057117', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Communicable Diseases', 'efo_term': 'fungal infectious disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1187 | Q34 | What are the names of the genes that are targeted by the drug Fedratinib Hydrochloride in the treatment of primary myelofibrosis? | In the context of primary myelofibrosis, the drug Fedratinib Hydrochloride targets the gene fms related receptor tyrosine kinase 3 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%primary myelofibrosis%" OR LOWER(efo_term) LIKE "%primary myelofibrosis%") AND (LOWER(drugName) LIKE "%fedratinib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%fedratinib hydrochloride%" OR LOWER(syns_list) LIKE "%fedratinib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933946', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933949', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933950', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933951', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933953', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933954', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933955', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933957', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933958', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933959', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933960', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933948', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933944', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933942', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933941', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933956', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933952', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933947', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933945', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933943', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.346 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of macular retinal edema? | In the context of macular retinal edema, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%macular retinal edema%" OR LOWER(efo_term) LIKE "%macular retinal edema%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227802', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228657', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228942', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229227', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229797', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230082', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230367', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230937', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231222', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231507', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231792', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232362', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230652', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228372', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227232', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226662', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226377', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232077', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229512', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228087', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227517', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226947', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1609 | Q34 | What are the names of the genes that are targeted by the drug Linaclotide in the treatment of constipation disorder? | In the context of constipation disorder, the drug Linaclotide targets the gene guanylate cyclase 2C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%constipation disorder%" OR LOWER(efo_term) LIKE "%constipation disorder%") AND (LOWER(drugName) LIKE "%linaclotide%" OR LOWER(tradeNames_list) LIKE "%linaclotide%" OR LOWER(syns_list) LIKE "%linaclotide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092109', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092121', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092125', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092129', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092137', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092141', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092145', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092153', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092157', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092161', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092165', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092173', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092177', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092181', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092185', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092189', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092193', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092197', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092201', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092205', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092209', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092217', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092221', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092225', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092213', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092149', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092101', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092093', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092089', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092117', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092169', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092133', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092113', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092105', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1092097', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'syns_list': "['ASP-0456', 'ASP0456', 'Linaclotide', 'MD-1100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1901 | Q34 | What are the names of the genes that are targeted by the drug Latanoprost in the treatment of open-angle glaucoma? | In the context of open-angle glaucoma, the drug Latanoprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%open-angle glaucoma%" OR LOWER(efo_term) LIKE "%open-angle glaucoma%") AND (LOWER(drugName) LIKE "%latanoprost%" OR LOWER(tradeNames_list) LIKE "%latanoprost%" OR LOWER(syns_list) LIKE "%latanoprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149124', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149106', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149103', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149112', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149118', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149109', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.929 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of Back pain? | In the context of Back pain, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%back pain%" OR LOWER(efo_term) LIKE "%back pain%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840001', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841107', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840949', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840396', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840475', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839764', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841581', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840870', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840554', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841186', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839843', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840080', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841028', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840238', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840712', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840159', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841502', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841660', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841423', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841265', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840317', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840633', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839922', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841739', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841344', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840791', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840764', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839974', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840843', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839737', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840053', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840369', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841001', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840290', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840448', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841159', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841238', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840132', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840527', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841317', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841396', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841080', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840606', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841475', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841554', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839816', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839895', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840211', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840685', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841633', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841712', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840922', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1043 | Q34 | What are the names of the genes that are targeted by the drug Levetiracetam in the treatment of Seizure? | In the context of Seizure, the drug Levetiracetam targets the gene calcium voltage-gated channel subunit alpha1 B and synaptic vesicle glycoprotein 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seizure%" OR LOWER(efo_term) LIKE "%seizure%") AND (LOWER(drugName) LIKE "%levetiracetam%" OR LOWER(tradeNames_list) LIKE "%levetiracetam%" OR LOWER(syns_list) LIKE "%levetiracetam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_915126', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914775', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915393', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915083', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914730', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914950', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914773', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914995', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914862', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914863', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915653', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915478', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914733', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915741', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914817', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914818', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914949', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915743', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914951', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915217', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914821', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914774', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915302', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914861', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915345', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915037', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915039', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915655', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914865', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915435', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914777', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915657', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914905', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914906', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915125', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915742', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915127', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915129', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914909', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915169', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915170', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915171', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915173', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915785', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915213', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915214', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915215', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915745', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914953', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915257', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915258', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915261', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914994', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915301', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915569', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915303', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915305', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915611', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915346', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915347', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915349', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915610', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915389', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915390', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915391', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915698', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915041', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915433', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915434', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915654', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915437', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915082', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915477', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915697', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915479', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915481', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915085', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915521', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915522', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915523', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915525', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915786', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915565', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915566', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915567', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915789', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915787', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915699', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915613', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915609', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915259', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914993', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914731', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914997', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915038', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915081', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915701', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914819', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914729', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914907', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1259 | Q34 | What are the names of the genes that are targeted by the drug Alpelisib in the treatment of breast cancer? | In the context of breast cancer, the drug Alpelisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%alpelisib%" OR LOWER(tradeNames_list) LIKE "%alpelisib%" OR LOWER(syns_list) LIKE "%alpelisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939631', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939694', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939715', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939736', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939673', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939589', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939547', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939526', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939757', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939652', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939610', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939568', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1331 | Q34 | What are the names of the genes that are targeted by the drug Ceritinib in the treatment of neoplasm? | In the context of neoplasm, the drug Ceritinib targets the gene ALK receptor tyrosine kinase, EMAP like 4 and nucleophosmin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%ceritinib%" OR LOWER(tradeNames_list) LIKE "%ceritinib%" OR LOWER(syns_list) LIKE "%ceritinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_991833', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991574', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991612', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991313', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991288', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991508', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991522', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991339', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991717', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991301', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991756', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991456', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991365', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991847', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991314', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991378', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991496', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991873', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991275', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991885', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991327', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991548', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991560', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991274', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991729', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991340', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991600', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991781', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991287', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991768', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991353', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991794', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991652', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991664', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991469', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991872', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991366', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991846', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991483', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991860', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991495', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991859', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991379', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991898', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991509', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991391', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991521', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991886', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991392', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991534', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991535', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991547', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991482', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991405', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991704', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991561', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991417', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991743', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991418', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991586', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991587', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991742', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991599', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991730', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991431', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991820', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991613', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991443', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991625', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991769', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991444', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991638', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991639', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991808', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991651', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991782', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991457', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991807', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991665', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991795', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991677', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991899', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991470', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991690', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991691', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991912', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991911', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991821', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991755', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991716', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991703', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991404', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991300', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991573', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991430', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991626', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991834', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991326', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991352', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991678', 'drugName': 'Ceritinib', 'tradeNames_list': "['Zykadia']", 'syns_list': "['Ceritinib', 'Ceritinib[mi]', 'LDK-378', 'LDK378', 'NVP-LDK-378-NXNVP-LDK378-NX']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1756 | Q34 | What are the names of the genes that are targeted by the drug Omeprazole in the treatment of gastric ulcer? | In the context of gastric ulcer, the drug Omeprazole targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastric ulcer%" OR LOWER(efo_term) LIKE "%gastric ulcer%") AND (LOWER(drugName) LIKE "%omeprazole%" OR LOWER(tradeNames_list) LIKE "%omeprazole%" OR LOWER(syns_list) LIKE "%omeprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1098039', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098249', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098319', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098179', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097876', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097864', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097900', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098109', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097969', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097888', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1659 | Q34 | What are the names of the genes that are targeted by the drug Spironolactone in the treatment of congestive heart failure? | In the context of congestive heart failure, the drug Spironolactone targets the gene nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congestive heart failure%" OR LOWER(efo_term) LIKE "%congestive heart failure%") AND (LOWER(drugName) LIKE "%spironolactone%" OR LOWER(tradeNames_list) LIKE "%spironolactone%" OR LOWER(syns_list) LIKE "%spironolactone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094539', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094653', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094615', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094463', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094349', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094387', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094577', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094501', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094425', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.239 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222199', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222329', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222069', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221939', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221874', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222264', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222134', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222004', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1461 | Q34 | What are the names of the genes that are targeted by the drug Tazarotene in the treatment of psoriasis? | In the context of psoriasis, the drug Tazarotene targets the gene retinoic acid receptor gamma, retinoic acid receptor beta and retinoic acid receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis%" OR LOWER(efo_term) LIKE "%psoriasis%") AND (LOWER(drugName) LIKE "%tazarotene%" OR LOWER(tradeNames_list) LIKE "%tazarotene%" OR LOWER(syns_list) LIKE "%tazarotene%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055477', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055491', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055493', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055499', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055507', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055509', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055515', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055523', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055525', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055531', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055533', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055541', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055547', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055549', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055517', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055485', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055469', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055461', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055459', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055539', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055501', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055483', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055475', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055467', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1170 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of soft tissue sarcoma? | Trametinib has not been approved by the FDA as a treatment for soft tissue sarcoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%soft tissue sarcoma%" OR LOWER(efo_term) LIKE "%soft tissue sarcoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928718', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928838', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928878', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928918', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928998', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929038', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929078', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929158', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929198', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929238', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929278', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929358', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929398', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929438', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929478', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929518', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929558', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929598', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929638', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929678', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929718', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929798', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929838', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929878', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929918', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929958', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930038', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930078', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930118', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930158', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930198', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930238', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930278', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930318', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930358', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930398', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930438', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930478', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930518', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930558', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930598', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930638', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930678', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930718', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930758', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930798', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930838', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930878', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930918', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930958', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930998', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931078', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931118', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931158', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931198', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931238', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931278', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931358', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931398', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931438', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931478', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931518', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931558', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931598', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931638', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931678', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931718', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931758', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931798', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931838', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931878', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931918', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931958', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931998', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932038', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932078', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932118', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932158', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932198', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932238', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932278', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932318', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932358', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932398', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932438', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932478', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931038', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929758', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929118', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928798', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928638', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928558', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928518', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931318', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929998', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929318', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928958', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928758', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928678', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928598', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1196 | Q34 | What are the names of the genes that are targeted by the drug Crizotinib in the treatment of diffuse large B-cell lymphoma? | In the context of diffuse large B-cell lymphoma, the drug Crizotinib targets the gene MET proto-oncogene, receptor tyrosine kinase, ALK receptor tyrosine kinase, EMAP like 4 and nucleophosmin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diffuse large b-cell lymphoma%" OR LOWER(efo_term) LIKE "%diffuse large b-cell lymphoma%") AND (LOWER(drugName) LIKE "%crizotinib%" OR LOWER(tradeNames_list) LIKE "%crizotinib%" OR LOWER(syns_list) LIKE "%crizotinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_934398', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934464', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934486', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934508', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934552', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934574', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934596', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934640', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934662', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934684', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934706', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934750', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934772', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934794', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934816', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934838', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934860', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934882', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934904', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934926', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934948', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934992', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935014', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935036', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935058', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935080', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935124', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935146', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935168', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935190', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935212', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935234', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935256', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935278', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935300', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935322', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935344', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935366', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935388', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935410', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935432', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935454', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935476', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935498', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935520', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935542', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935564', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935586', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935608', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935630', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935652', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935696', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935718', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935740', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935762', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935784', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935806', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935850', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935872', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935894', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935916', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935938', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935960', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935982', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936004', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936026', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936048', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936070', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936092', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936114', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935674', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_934970', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934618', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934442', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934354', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934310', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934288', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935828', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935102', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934728', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934530', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934420', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934376', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934332', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.419 | Q34 | What are the names of the genes that are targeted by the drug Fenofibrate in the treatment of Hypercholesterolemia? | In the context of Hypercholesterolemia, the drug Fenofibrate targets the gene peroxisome proliferator activated receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypercholesterolemia%" OR LOWER(efo_term) LIKE "%hypercholesterolemia%") AND (LOWER(drugName) LIKE "%fenofibrate%" OR LOWER(tradeNames_list) LIKE "%fenofibrate%" OR LOWER(syns_list) LIKE "%fenofibrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243842', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243818', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243866', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243872', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243836', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243890', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243896', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243854', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243860', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243938', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243967', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243878', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243884', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244083', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244112', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244141', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244170', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244199', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244228', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244257', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244286', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244344', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244373', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244402', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244431', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244315', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243830', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243812', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244025', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244054', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243902', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243996', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243848', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243824', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243904', 'drugName': 'Choline Fenofibrate', 'tradeNames_list': "['Trilipix']", 'syns_list': "['ABT-335', 'Choline fenofibrate', 'Fenofibric acid choline salt']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243909', 'drugName': 'Choline Fenofibrate', 'tradeNames_list': "['Trilipix']", 'syns_list': "['ABT-335', 'Choline fenofibrate', 'Fenofibric acid choline salt']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.113 | Q34 | What are the names of the genes that are targeted by the drug Duloxetine Hydrochloride in the treatment of neuropathic pain? | In the context of neuropathic pain, the drug Duloxetine Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neuropathic pain%" OR LOWER(efo_term) LIKE "%neuropathic pain%") AND (LOWER(drugName) LIKE "%duloxetine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%duloxetine hydrochloride%" OR LOWER(syns_list) LIKE "%duloxetine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206078', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206126', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206142', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206158', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206190', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206206', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206222', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206254', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206270', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206286', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206302', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206334', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206350', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206366', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206382', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206398', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206414', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206430', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206446', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206462', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206478', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206494', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206238', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206110', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206046', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206014', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205998', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206318', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206174', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206094', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206062', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206030', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.625 | Q34 | What are the names of the genes that are targeted by the drug Sorafenib Tosylate in the treatment of chromophobe renal cell carcinoma? | In the context of chromophobe renal cell carcinoma, the drug Sorafenib Tosylate targets the gene kinase insert domain receptor, B-Raf proto-oncogene, serine/threonine kinase, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 3, KIT proto-oncogene, receptor tyrosine kinase, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, Raf-1 proto-oncogene, serine/threonine kinase and ret proto-oncogene. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chromophobe renal cell carcinoma%" OR LOWER(efo_term) LIKE "%chromophobe renal cell carcinoma%") AND (LOWER(drugName) LIKE "%sorafenib tosylate%" OR LOWER(tradeNames_list) LIKE "%sorafenib tosylate%" OR LOWER(syns_list) LIKE "%sorafenib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_683536', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683719', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683780', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683841', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683963', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684024', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684085', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684207', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684268', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684329', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684390', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684512', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684573', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684634', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684695', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684756', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684817', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684878', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684939', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685000', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685061', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685183', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685244', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685305', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685366', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685427', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685549', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685610', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685671', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685732', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685793', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685854', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685915', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685122', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684146', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683658', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683414', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683292', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683231', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685488', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684451', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683902', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683597', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683475', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683353', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.539 | Q34 | What are the names of the genes that are targeted by the drug Azelastine Hydrochloride in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Azelastine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%azelastine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%azelastine hydrochloride%" OR LOWER(syns_list) LIKE "%azelastine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455906', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455930', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455938', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455946', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455890', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455874', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455866', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455922', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455914', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455898', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455882', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1484 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of cancer? | In the context of cancer, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1058890', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056780', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058567', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057924', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058712', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061305', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058873', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059034', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059373', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057762', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060017', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058551', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056797', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061127', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060966', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058728', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057440', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061610', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061449', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061627', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057102', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057602', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059051', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059195', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059534', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059517', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058246', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060178', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056796', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060161', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057279', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060322', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056958', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060339', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060483', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061288', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058084', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060983', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060982', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061144', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057424', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061143', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057441', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061932', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061304', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061466', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061465', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061788', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061626', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061787', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061771', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057601', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058229', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057119', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059356', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059050', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059212', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059855', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058245', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059533', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057746', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059839', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057763', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059695', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059694', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060661', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058390', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060016', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060000', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060177', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056957', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057907', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057923', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060660', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057280', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058407', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058406', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060644', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060338', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060500', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060499', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061948', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058068', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060821', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058085', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062093', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061949', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060805', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059856', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059372', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058568', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057585', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057118', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059211', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059678', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057263', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060822', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058889', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056941', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058729', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1428 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of Hypercholesterolemia? | In the context of Hypercholesterolemia, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypercholesterolemia%" OR LOWER(efo_term) LIKE "%hypercholesterolemia%") AND (LOWER(drugName) LIKE "%amlodipine besylate%" OR LOWER(tradeNames_list) LIKE "%amlodipine besylate%" OR LOWER(syns_list) LIKE "%amlodipine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043698', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043718', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043726', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043732', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043746', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043754', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043760', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043774', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043782', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043788', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043796', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043810', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043816', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043824', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043830', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043838', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043844', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043852', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043858', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043866', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043872', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043886', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043894', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043900', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043908', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043914', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043928', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043936', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043942', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043950', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043956', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043964', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043970', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043978', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043984', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043992', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043880', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043768', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043712', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043684', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043670', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043662', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043922', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043802', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043740', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043704', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043690', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043676', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1431 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%amlodipine besylate%" OR LOWER(tradeNames_list) LIKE "%amlodipine besylate%" OR LOWER(syns_list) LIKE "%amlodipine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043735', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043777', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043791', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043805', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043833', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043847', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043861', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043889', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043903', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043917', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043931', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043959', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043973', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043987', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043875', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043763', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043707', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043679', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043665', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043945', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043819', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043749', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043721', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043693', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1064 | Q34 | What are the names of the genes that are targeted by the drug Imiquimod in the treatment of skin basal cell carcinoma? | In the context of skin basal cell carcinoma, the drug Imiquimod targets the gene toll like receptor 7. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%skin basal cell carcinoma%" OR LOWER(efo_term) LIKE "%skin basal cell carcinoma%") AND (LOWER(drugName) LIKE "%imiquimod%" OR LOWER(tradeNames_list) LIKE "%imiquimod%" OR LOWER(syns_list) LIKE "%imiquimod%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919782', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919941', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919994', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920047', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920153', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920206', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920259', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920312', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919888', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919676', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919570', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919517', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920100', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919835', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919729', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919623', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.761 | Q34 | What are the names of the genes that are targeted by the drug Naltrexone in the treatment of alcohol abuse? | In the context of alcohol abuse, the drug Naltrexone targets the gene opioid receptor mu 1, opioid receptor kappa 1 and opioid receptor delta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%alcohol abuse%" OR LOWER(efo_term) LIKE "%alcohol abuse%") AND (LOWER(drugName) LIKE "%naltrexone%" OR LOWER(tradeNames_list) LIKE "%naltrexone%" OR LOWER(syns_list) LIKE "%naltrexone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_785289', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1'}, {'UUID': 'DrugTargetsIndication121923_text_785109', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785064', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785199', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_785244', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1'}, {'UUID': 'DrugTargetsIndication121923_text_785154', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'syns_list': "['EN-1639A', 'EN-1639A FREE BASE', 'EN-1639A [AS HYDROCHLORIDE]NSC-758439', 'Naltrexone', 'Revia']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1519 | Q34 | What are the names of the genes that are targeted by the drug Telmisartan in the treatment of diabetes mellitus? | In the context of diabetes mellitus, the drug Telmisartan targets the gene angiotensin II receptor type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes mellitus%" OR LOWER(efo_term) LIKE "%diabetes mellitus%") AND (LOWER(drugName) LIKE "%telmisartan%" OR LOWER(tradeNames_list) LIKE "%telmisartan%" OR LOWER(syns_list) LIKE "%telmisartan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072709', 'drugName': 'Telmisartan', 'tradeNames_list': "['Micardis', 'Telmisartan', 'Tolura']", 'syns_list': "['BIBR 277 SE', 'BIBR-277', 'BIBR-277 SE', 'BIBR-277-SE', 'BIBR-277SEC09CA07', 'Kinzalmono', 'Pritor', 'Semintra', 'TelmisartanTelmisartan actavis', 'Telmisartan teva']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072705', 'drugName': 'Telmisartan', 'tradeNames_list': "['Micardis', 'Telmisartan', 'Tolura']", 'syns_list': "['BIBR 277 SE', 'BIBR-277', 'BIBR-277 SE', 'BIBR-277-SE', 'BIBR-277SEC09CA07', 'Kinzalmono', 'Pritor', 'Semintra', 'TelmisartanTelmisartan actavis', 'Telmisartan teva']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1628 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of Respiratory Syncytial Virus Infection? | Dabigatran has not been approved by the FDA as a treatment for Respiratory Syncytial Virus Infection, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%respiratory syncytial virus infection%" OR LOWER(efo_term) LIKE "%respiratory syncytial virus infection%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1093461', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093494', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093505', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093516', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093538', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093549', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093560', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093582', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093593', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093604', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093615', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093637', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093648', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093659', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093670', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093681', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093692', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093703', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093714', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093725', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093736', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093758', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093769', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093780', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093791', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093802', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093824', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093835', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093846', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093857', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093868', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093879', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093890', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093901', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093912', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093923', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093934', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093945', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093956', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093967', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093978', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093989', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094000', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094011', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094022', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093747', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093571', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093483', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093439', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093417', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093406', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093813', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093626', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093527', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093472', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093450', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093428', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Respiratory Syncytial Virus Infections', 'efo_term': 'Respiratory Syncytial Virus Infection', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1593 | Q34 | What are the names of the genes that are targeted by the drug Tacrolimus in the treatment of immune system disease? | In the context of immune system disease, the drug Tacrolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%tacrolimus%" OR LOWER(tradeNames_list) LIKE "%tacrolimus%" OR LOWER(syns_list) LIKE "%tacrolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091477', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091483', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091485', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091487', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091491', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091493', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091495', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091499', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091501', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091503', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091505', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091509', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091511', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091513', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091515', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091517', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091519', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091521', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091523', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091525', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091527', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091531', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091533', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091535', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091537', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091539', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091543', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091545', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091547', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091549', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091551', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091553', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091555', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091557', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091559', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091561', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091563', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091565', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091567', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091569', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091571', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091573', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091575', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091577', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091579', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091581', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091583', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091585', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091587', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091589', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091591', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091595', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091597', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091599', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091601', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091603', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091605', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091609', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091611', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091613', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091615', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091617', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091619', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091621', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091623', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091625', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091627', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091629', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091631', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091633', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091593', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091529', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091497', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091481', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091473', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091469', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091467', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091607', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091541', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091507', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091489', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091479', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091475', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091471', 'drugName': 'Tacrolimus', 'tradeNames_list': "['Adoport', 'Advagraf', 'Astagraf xl', 'Capexion', 'Envarsus', 'Envarsus xrModigraf', 'Perixis', 'Prograf', 'Protopic', 'Tacni', 'Tacrolimus', 'Vivadex']", 'syns_list': "['FK 506', 'FR900506', 'Tacrolimus', 'Tacrolimus hydrate']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.930 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of Dysmenorrhea? | In the context of Dysmenorrhea, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dysmenorrhea%" OR LOWER(efo_term) LIKE "%dysmenorrhea%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840160', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840397', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840476', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840555', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840713', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840792', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840871', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841029', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841108', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841187', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841266', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841424', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841503', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841582', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841661', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841740', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840950', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840318', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840002', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839844', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839765', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841345', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840634', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840239', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840081', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839923', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1654 | Q34 | What are the names of the genes that are targeted by the drug Abiraterone Acetate in the treatment of prostate carcinoma? | In the context of prostate carcinoma, the drug Abiraterone Acetate targets the gene cytochrome P450 family 17 subfamily A member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate carcinoma%" OR LOWER(efo_term) LIKE "%prostate carcinoma%") AND (LOWER(drugName) LIKE "%abiraterone acetate%" OR LOWER(tradeNames_list) LIKE "%abiraterone acetate%" OR LOWER(syns_list) LIKE "%abiraterone acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094287', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094300', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1304 | Q34 | What are the names of the genes that are targeted by the drug Nitroglycerin in the treatment of congestive heart failure? | In the context of congestive heart failure, the drug Nitroglycerin targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congestive heart failure%" OR LOWER(efo_term) LIKE "%congestive heart failure%") AND (LOWER(drugName) LIKE "%nitroglycerin%" OR LOWER(tradeNames_list) LIKE "%nitroglycerin%" OR LOWER(syns_list) LIKE "%nitroglycerin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972645', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972713', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972577', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972509', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972475', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972679', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972611', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972543', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1831 | Q34 | What are the names of the genes that are targeted by the drug Cyclosporine in the treatment of keratoconjunctivitis? | In the context of keratoconjunctivitis, the drug Cyclosporine targets the gene peptidylprolyl isomerase A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%keratoconjunctivitis%" OR LOWER(efo_term) LIKE "%keratoconjunctivitis%") AND (LOWER(drugName) LIKE "%cyclosporine%" OR LOWER(tradeNames_list) LIKE "%cyclosporine%" OR LOWER(syns_list) LIKE "%cyclosporine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1101284', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101665', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101792', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101919', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102173', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102300', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102427', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102681', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102808', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102935', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1103062', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101538', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101030', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100776', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100649', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102554', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102046', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101411', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101157', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100903', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.431 | Q34 | What are the names of the genes that are targeted by the drug Selexipag in the treatment of idiopathic pulmonary arterial hypertension? | In the context of idiopathic pulmonary arterial hypertension, the drug Selexipag targets the gene prostaglandin I2 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%idiopathic pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%idiopathic pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%selexipag%" OR LOWER(tradeNames_list) LIKE "%selexipag%" OR LOWER(syns_list) LIKE "%selexipag%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_246146', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246158', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246162', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246166', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246174', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246178', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246182', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246190', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246194', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246198', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246202', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246210', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246214', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246218', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246222', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246226', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246230', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246234', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246238', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246242', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246246', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246254', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246258', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246262', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246266', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246270', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246278', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246282', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246286', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246290', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246294', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246298', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246302', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246306', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246310', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246314', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246318', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246322', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246326', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246330', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246250', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246186', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246154', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246138', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246130', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246126', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246274', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246206', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246170', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246150', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246142', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246134', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1173 | Q34 | What are the names of the genes that are targeted by the drug Selumetinib Sulfate in the treatment of neurofibromatosis type 1? | In the context of neurofibromatosis type 1, the drug Selumetinib Sulfate targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neurofibromatosis type 1%" OR LOWER(efo_term) LIKE "%neurofibromatosis type 1%") AND (LOWER(drugName) LIKE "%selumetinib sulfate%" OR LOWER(tradeNames_list) LIKE "%selumetinib sulfate%" OR LOWER(syns_list) LIKE "%selumetinib sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_932837', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932855', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932861', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932867', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932879', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932885', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932891', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932897', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932849', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932825', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932813', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932807', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932873', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932843', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932831', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_932819', 'drugName': 'Selumetinib Sulfate', 'tradeNames_list': "['Koselugo']", 'syns_list': "['AZD-6244 HYD-SULFATE', 'AZD-6244 HYDROGEN SULFATE', 'AZD6244 HYD-SULFATEAZD6244 HYDROGEN SULFATE', 'Azd-6244 hydrogen sulphateAzd6244 hydrogen sulphate', 'Selumetinib sulfate', 'Selumetinib sulphate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neurofibromatosis 1', 'efo_term': 'neurofibromatosis type 1', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.709 | Q34 | What are the names of the genes that are targeted by the drug Nilotinib in the treatment of cancer? | In the context of cancer, the drug Nilotinib targets the gene ABL proto-oncogene 1, non-receptor tyrosine kinase and BCR activator of RhoGEF and GTPase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%nilotinib%" OR LOWER(tradeNames_list) LIKE "%nilotinib%" OR LOWER(syns_list) LIKE "%nilotinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_747506', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746256', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746706', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747031', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747731', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747981', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748106', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746056', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746306', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746431', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746806', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747081', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747206', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747706', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747631', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747781', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747806', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748081', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748006', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748156', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748181', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745956', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746106', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746131', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746406', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746331', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746506', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747006', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746731', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746881', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746906', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747181', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747106', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747256', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747281', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747906', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747531', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747681', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747656', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747881', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747756', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747856', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747831', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748281', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_747956', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748056', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748031', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748256', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748131', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748231', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748206', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745906', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746006', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745981', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746206', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746081', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746181', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746606', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746281', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746381', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746356', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746581', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746456', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746556', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746531', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747406', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746681', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746781', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746756', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746981', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746856', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746956', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746931', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747381', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747056', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747156', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747131', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747356', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747231', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747331', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747306', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748306', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_747481', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747581', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747556', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_748356', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_748331', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_747431', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746631', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746231', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746031', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745931', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745881', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746156', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746481', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746831', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747606', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747931', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746656', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747456', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1230 | Q34 | What are the names of the genes that are targeted by the drug Ribavirin in the treatment of fibrosis? | In the context of fibrosis, the drug Ribavirin targets the gene inosine monophosphate dehydrogenase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fibrosis%" OR LOWER(efo_term) LIKE "%fibrosis%") AND (LOWER(drugName) LIKE "%ribavirin%" OR LOWER(tradeNames_list) LIKE "%ribavirin%" OR LOWER(syns_list) LIKE "%ribavirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937567', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'fibrosis', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}, {'UUID': 'DrugTargetsIndication121923_text_937565', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}, {'UUID': 'DrugTargetsIndication121923_text_937592', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'fibrosis', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}, {'UUID': 'DrugTargetsIndication121923_text_937590', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'syns_list': "['Cotronak', 'NSC-163039', 'Ribavirin', 'Ribavirin biopartnersRibavirin mylan', 'Ribavirin teva', 'SCH 18908', 'SCH-18908', 'Tribavirin']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1530 | Q34 | What are the names of the genes that are targeted by the drug Aprepitant in the treatment of Chemotherapy-induced nausea and vomiting? | In the context of Chemotherapy-induced nausea and vomiting, the drug Aprepitant targets the gene tachykinin receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chemotherapy-induced nausea and vomiting%" OR LOWER(efo_term) LIKE "%chemotherapy-induced nausea and vomiting%") AND (LOWER(drugName) LIKE "%aprepitant%" OR LOWER(tradeNames_list) LIKE "%aprepitant%" OR LOWER(syns_list) LIKE "%aprepitant%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072807', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072852', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072853', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072875', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072898', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072899', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072921', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072944', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072945', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072967', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072968', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072991', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073013', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073014', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073036', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073037', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073059', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073060', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073082', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073083', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073105', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073156', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073161', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073166', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073171', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073176', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073186', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073106', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072922', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072830', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072784', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072761', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072760', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073181', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072990', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072876', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072829', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072806', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072783', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.559 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine Hydrochloride in the treatment of prostate carcinoma? | In the context of prostate carcinoma, the drug Lidocaine Hydrochloride targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate carcinoma%" OR LOWER(efo_term) LIKE "%prostate carcinoma%") AND (LOWER(drugName) LIKE "%lidocaine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%lidocaine hydrochloride%" OR LOWER(syns_list) LIKE "%lidocaine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_637008', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637068', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637088', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637108', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637148', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637168', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637188', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637228', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637248', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637268', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637288', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637328', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637348', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637368', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637388', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637408', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637428', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637448', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637468', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637488', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637508', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637548', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637568', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637588', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637608', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637628', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637668', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637688', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637528', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637208', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637048', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_636968', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636928', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636908', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637648', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637308', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637128', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637028', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_636988', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_636948', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1549 | Q34 | What are the names of the genes that are targeted by the drug Lemborexant in the treatment of insomnia? | In the context of insomnia, the drug Lemborexant targets the gene hypocretin receptor 2 and hypocretin receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%insomnia%" OR LOWER(efo_term) LIKE "%insomnia%") AND (LOWER(drugName) LIKE "%lemborexant%" OR LOWER(tradeNames_list) LIKE "%lemborexant%" OR LOWER(syns_list) LIKE "%lemborexant%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1076427', 'drugName': 'Lemborexant', 'tradeNames_list': "['Dayvigo']", 'syns_list': "['E-2006', 'E2006', 'Lemborexant']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076441', 'drugName': 'Lemborexant', 'tradeNames_list': "['Dayvigo']", 'syns_list': "['E-2006', 'E2006', 'Lemborexant']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076413', 'drugName': 'Lemborexant', 'tradeNames_list': "['Dayvigo']", 'syns_list': "['E-2006', 'E2006', 'Lemborexant']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076399', 'drugName': 'Lemborexant', 'tradeNames_list': "['Dayvigo']", 'syns_list': "['E-2006', 'E2006', 'Lemborexant']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076392', 'drugName': 'Lemborexant', 'tradeNames_list': "['Dayvigo']", 'syns_list': "['E-2006', 'E2006', 'Lemborexant']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076434', 'drugName': 'Lemborexant', 'tradeNames_list': "['Dayvigo']", 'syns_list': "['E-2006', 'E2006', 'Lemborexant']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076420', 'drugName': 'Lemborexant', 'tradeNames_list': "['Dayvigo']", 'syns_list': "['E-2006', 'E2006', 'Lemborexant']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076406', 'drugName': 'Lemborexant', 'tradeNames_list': "['Dayvigo']", 'syns_list': "['E-2006', 'E2006', 'Lemborexant']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.354 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of sarcoidosis? | In the context of sarcoidosis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sarcoidosis%" OR LOWER(efo_term) LIKE "%sarcoidosis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227810', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228665', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228950', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229235', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229805', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230090', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230375', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230945', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231230', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231515', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231800', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232370', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230660', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228380', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227240', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226670', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226385', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232085', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229520', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228095', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227525', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226955', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1366 | Q34 | What are the names of the genes that are targeted by the drug Ibrutinib in the treatment of Mantle cell lymphoma? | In the context of Mantle cell lymphoma, the drug Ibrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mantle cell lymphoma%" OR LOWER(efo_term) LIKE "%mantle cell lymphoma%") AND (LOWER(drugName) LIKE "%ibrutinib%" OR LOWER(tradeNames_list) LIKE "%ibrutinib%" OR LOWER(syns_list) LIKE "%ibrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_995267', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995405', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995451', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995497', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995589', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995635', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995681', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995773', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995819', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995865', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995911', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996003', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996049', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996095', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996141', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996187', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996233', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996279', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996325', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996371', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996417', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996509', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996555', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996601', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996647', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996693', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996785', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996831', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996877', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996923', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996969', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997015', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997061', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997107', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997153', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997199', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997245', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997291', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997337', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997383', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997429', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997475', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997521', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997567', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997613', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997659', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997705', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997751', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997797', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997843', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997889', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997981', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998027', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998073', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998119', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998165', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998211', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998303', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998349', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998395', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998441', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998487', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998533', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998579', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998625', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998671', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998717', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998763', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998809', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998855', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998901', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998947', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998993', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999039', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999085', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999131', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999177', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999223', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999269', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999315', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999361', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999407', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999453', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999499', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999545', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999591', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997935', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996463', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995727', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995359', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995175', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995083', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995037', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998257', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996739', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995957', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995543', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995313', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995221', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995129', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.851 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of peptic ulcer disease? | In the context of peptic ulcer disease, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%peptic ulcer disease%" OR LOWER(efo_term) LIKE "%peptic ulcer disease%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833504', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833060', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832949', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833282', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833393', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833171', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1591 | Q34 | What are the names of the genes that are targeted by the drug Temsirolimus in the treatment of renal cell carcinoma? | In the context of renal cell carcinoma, the drug Temsirolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal cell carcinoma%" OR LOWER(efo_term) LIKE "%renal cell carcinoma%") AND (LOWER(drugName) LIKE "%temsirolimus%" OR LOWER(tradeNames_list) LIKE "%temsirolimus%" OR LOWER(syns_list) LIKE "%temsirolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091090', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091315', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091390', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091465', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090940', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090790', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090715', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091240', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091165', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091015', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090865', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.101 | Q34 | What are the names of the genes that are targeted by the drug Granisetron in the treatment of post operative nausea and vomiting? | In the context of post operative nausea and vomiting, the drug Granisetron targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%post operative nausea and vomiting%" OR LOWER(efo_term) LIKE "%post operative nausea and vomiting%") AND (LOWER(drugName) LIKE "%granisetron%" OR LOWER(tradeNames_list) LIKE "%granisetron%" OR LOWER(syns_list) LIKE "%granisetron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205822', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205766', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205752', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205794', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205808', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205780', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.222 | Q34 | What are the names of the genes that are targeted by the drug Desoximetasone in the treatment of psoriasis vulgaris? | In the context of psoriasis vulgaris, the drug Desoximetasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis vulgaris%" OR LOWER(efo_term) LIKE "%psoriasis vulgaris%") AND (LOWER(drugName) LIKE "%desoximetasone%" OR LOWER(tradeNames_list) LIKE "%desoximetasone%" OR LOWER(syns_list) LIKE "%desoximetasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220822', 'drugName': 'Desoximetasone', 'tradeNames_list': "['Desoximetasone', 'Stiedex', 'Stiedex lp', 'Stiedex lpn', 'TopicortTopicort lp']", 'syns_list': "['A-41-304', 'A-41304', 'Desoximetasone', 'Desoxymethasone', 'HOE 304HOE-304', 'J83.644C', 'NSC-759189', 'R 2113', 'R-2113']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220825', 'drugName': 'Desoximetasone', 'tradeNames_list': "['Desoximetasone', 'Stiedex', 'Stiedex lp', 'Stiedex lpn', 'TopicortTopicort lp']", 'syns_list': "['A-41-304', 'A-41304', 'Desoximetasone', 'Desoxymethasone', 'HOE 304HOE-304', 'J83.644C', 'NSC-759189', 'R 2113', 'R-2113']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1904 | Q34 | What are the names of the genes that are targeted by the drug Bimatoprost in the treatment of open-angle glaucoma? | In the context of open-angle glaucoma, the drug Bimatoprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%open-angle glaucoma%" OR LOWER(efo_term) LIKE "%open-angle glaucoma%") AND (LOWER(drugName) LIKE "%bimatoprost%" OR LOWER(tradeNames_list) LIKE "%bimatoprost%" OR LOWER(syns_list) LIKE "%bimatoprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149175', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149202', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149211', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149220', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149238', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149247', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149256', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149274', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149283', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149292', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149301', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149319', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149328', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149337', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149346', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149355', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149364', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149373', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149382', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149391', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149400', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149265', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149193', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149157', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149139', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149130', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149310', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149229', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149184', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149166', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149148', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.699 | Q34 | What are the names of the genes that are targeted by the drug Apixaban in the treatment of deep vein thrombosis? | In the context of deep vein thrombosis, the drug Apixaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%deep vein thrombosis%" OR LOWER(efo_term) LIKE "%deep vein thrombosis%") AND (LOWER(drugName) LIKE "%apixaban%" OR LOWER(tradeNames_list) LIKE "%apixaban%" OR LOWER(syns_list) LIKE "%apixaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710509', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710596', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710625', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710654', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710712', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710741', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710770', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710567', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710451', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710393', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710364', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710683', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710538', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710480', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710422', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1638 | Q34 | What are the names of the genes that are targeted by the drug Atogepant in the treatment of migraine disorder? | In the context of migraine disorder, the drug Atogepant targets the gene calcitonin receptor like receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%atogepant%" OR LOWER(tradeNames_list) LIKE "%atogepant%" OR LOWER(syns_list) LIKE "%atogepant%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094046', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094049', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094050', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094051', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094048', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094044', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094042', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094041', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094052', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094047', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094045', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094043', 'drugName': 'Atogepant', 'tradeNames_list': "['Qulipta']", 'syns_list': "['AGN-241689', 'Atogepant', 'MK-8031']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1370 | Q34 | What are the names of the genes that are targeted by the drug Zanubrutinib in the treatment of neoplasm? | In the context of neoplasm, the drug Zanubrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%zanubrutinib%" OR LOWER(tradeNames_list) LIKE "%zanubrutinib%" OR LOWER(syns_list) LIKE "%zanubrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1025140', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025174', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025173', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025190', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025106', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025088', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025208', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025157', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025242', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025105', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025123', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025224', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025241', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025122', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025225', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025207', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025139', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025191', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025156', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025089', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025083', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025100', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025168', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025185', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025134', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025202', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025117', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025151', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025219', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025236', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1712 | Q34 | What are the names of the genes that are targeted by the drug Triptorelin Pamoate in the treatment of Central precocious puberty? | In the context of Central precocious puberty, the drug Triptorelin Pamoate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%central precocious puberty%" OR LOWER(efo_term) LIKE "%central precocious puberty%") AND (LOWER(drugName) LIKE "%triptorelin pamoate%" OR LOWER(tradeNames_list) LIKE "%triptorelin pamoate%" OR LOWER(syns_list) LIKE "%triptorelin pamoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097287', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'syns_list': "['Salvacyl', 'Triptorelin (as embonate)', 'Triptorelin embonateTriptorelin pamoate']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097294', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'syns_list': "['Salvacyl', 'Triptorelin (as embonate)', 'Triptorelin embonateTriptorelin pamoate']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1017 | Q34 | What are the names of the genes that are targeted by the drug Glycopyrrolate in the treatment of gastrointestinal disease? | In the context of gastrointestinal disease, the drug Glycopyrrolate targets the gene cholinergic receptor muscarinic 3 and cholinergic receptor muscarinic 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastrointestinal disease%" OR LOWER(efo_term) LIKE "%gastrointestinal disease%") AND (LOWER(drugName) LIKE "%glycopyrrolate%" OR LOWER(tradeNames_list) LIKE "%glycopyrrolate%" OR LOWER(syns_list) LIKE "%glycopyrrolate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857535', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857562', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857571', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857580', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857598', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857607', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857616', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857634', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857643', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857652', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857661', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857679', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857688', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857697', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857706', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857715', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857724', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857733', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857742', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857751', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857760', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857778', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857787', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857769', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857625', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857553', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857499', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857490', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857517', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857670', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857589', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857544', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857526', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857508', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Digestive System Diseases', 'efo_term': 'gastrointestinal disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.318 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of eosinophilic pneumonia? | In the context of eosinophilic pneumonia, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eosinophilic pneumonia%" OR LOWER(efo_term) LIKE "%eosinophilic pneumonia%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227774', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228629', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228914', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229199', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229769', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230054', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230339', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230909', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231194', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231479', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231764', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232334', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230624', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228344', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227204', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226634', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226349', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232049', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229484', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228059', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227489', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226919', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.130 | Q34 | What are the names of the genes that are targeted by the drug Vilazodone Hydrochloride in the treatment of unipolar depression? | In the context of unipolar depression, the drug Vilazodone Hydrochloride targets the gene solute carrier family 6 member 4 and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%vilazodone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%vilazodone hydrochloride%" OR LOWER(syns_list) LIKE "%vilazodone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_207060', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207063', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207064', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207065', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207067', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207068', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207069', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207071', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207072', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207073', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207074', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207076', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207077', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207078', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207079', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207080', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207081', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207082', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207083', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207084', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207085', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207087', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207088', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207089', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207090', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207091', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207093', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207094', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207095', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207096', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207097', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207098', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207099', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207100', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207101', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207102', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207086', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207070', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207062', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207058', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207056', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207055', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207092', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_207075', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207066', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207061', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207059', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_207057', 'drugName': 'Vilazodone Hydrochloride', 'tradeNames_list': "['Viibryd']", 'syns_list': "['EMD 68 843', 'EMD-68843', 'SB-659746-A', 'SB659746-A', 'Vilazodone hclVilazodone hydrochloride']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.894 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of juvenile idiopathic arthritis? | In the context of juvenile idiopathic arthritis, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%juvenile idiopathic arthritis%" OR LOWER(efo_term) LIKE "%juvenile idiopathic arthritis%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838130', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838181', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838198', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838215', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838249', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838266', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838283', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838300', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838164', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838096', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838062', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838045', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838232', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838147', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838113', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838079', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.212 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of asthma? | In the context of asthma, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218718', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219342', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219550', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219758', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220174', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220382', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220590', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220798', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219134', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218302', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217886', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217678', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219966', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218926', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218510', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218094', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1235 | Q34 | What are the names of the genes that are targeted by the drug Mirabegron in the treatment of Urinary incontinence? | In the context of Urinary incontinence, the drug Mirabegron targets the gene adrenoceptor beta 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urinary incontinence%" OR LOWER(efo_term) LIKE "%urinary incontinence%") AND (LOWER(drugName) LIKE "%mirabegron%" OR LOWER(tradeNames_list) LIKE "%mirabegron%" OR LOWER(syns_list) LIKE "%mirabegron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937726', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937756', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937758', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937772', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937788', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937790', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937804', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937820', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937822', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937836', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937838', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937854', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937868', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937870', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937884', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937886', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937900', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937902', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937916', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937918', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937932', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937948', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937950', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937964', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937966', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937980', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937996', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937998', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938012', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938014', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938028', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938030', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938044', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938046', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938060', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938062', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938076', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938078', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938092', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938094', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938108', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938110', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938124', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938126', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938140', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938142', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938156', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938158', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938172', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938174', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938188', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938204', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938206', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938220', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938222', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938236', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938238', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938254', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938190', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937934', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937806', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937742', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937710', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937694', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937692', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938252', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937982', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937852', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937774', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937740', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937724', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937708', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1916 | Q34 | What are the names of the genes that are targeted by the drug Teriflunomide in the treatment of immune system disease? | In the context of immune system disease, the drug Teriflunomide targets the gene dihydroorotate dehydrogenase (quinone). | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%teriflunomide%" OR LOWER(tradeNames_list) LIKE "%teriflunomide%" OR LOWER(syns_list) LIKE "%teriflunomide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191752', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191767', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191772', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191777', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191762', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191742', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191732', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191727', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191782', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191757', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191747', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191737', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.584 | Q34 | What are the names of the genes that are targeted by the drug Erlosamide in the treatment of epilepsy? | In the context of epilepsy, the drug Erlosamide targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%epilepsy%" OR LOWER(efo_term) LIKE "%epilepsy%") AND (LOWER(drugName) LIKE "%erlosamide%" OR LOWER(tradeNames_list) LIKE "%erlosamide%" OR LOWER(syns_list) LIKE "%erlosamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_646292', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645347', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645956', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645515', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645137', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646481', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645221', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645305', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645788', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645389', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645998', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646103', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645557', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_646376', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645116', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646397', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645158', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646523', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_645200', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646544', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_645242', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645284', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645704', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645326', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645830', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645368', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645410', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_646082', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645452', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_646019', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645494', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_646145', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645536', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_646166', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645578', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_646460', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645620', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_646355', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644717', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646439', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644864', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646418', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644654', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646628', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_644885', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646502', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_644738', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646607', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_644906', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646586', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646565', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_644927', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645662', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_644759', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645746', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_644948', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645725', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645914', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644969', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645809', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_644780', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645893', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644990', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645872', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644633', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646250', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645011', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645977', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644801', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646061', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645032', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646040', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644696', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646229', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645053', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646124', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644822', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646208', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645074', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646187', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644612', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646649', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_645095', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646313', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644843', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646691', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646670', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646271', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645935', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645767', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645683', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645641', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645263', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_644675', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645851', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645473', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_646334', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645179', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645431', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645599', 'drugName': 'Erlosamide', 'tradeNames_list': "['Lacosamide', 'Vimpat']", 'syns_list': "['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.436 | Q34 | What are the names of the genes that are targeted by the drug Carvedilol in the treatment of heart failure? | In the context of heart failure, the drug Carvedilol targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%heart failure%" OR LOWER(efo_term) LIKE "%heart failure%") AND (LOWER(drugName) LIKE "%carvedilol%" OR LOWER(tradeNames_list) LIKE "%carvedilol%" OR LOWER(syns_list) LIKE "%carvedilol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_357043', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357104', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357107', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357136', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357168', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357171', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357200', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357232', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357235', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357264', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357267', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357299', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357328', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357331', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357360', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357363', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357392', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357395', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357424', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357427', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357456', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357488', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357491', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357520', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357523', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357552', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357584', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357587', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357616', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357619', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357648', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357651', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357680', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357683', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357712', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357715', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357744', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357747', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357776', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357779', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357808', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357811', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357840', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357843', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357872', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357875', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357904', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357907', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357936', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357939', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357968', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358000', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358003', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358032', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358035', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358064', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358067', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358099', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358128', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358131', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358160', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358163', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358192', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358195', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358224', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358227', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358256', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358259', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358288', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358291', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358320', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358323', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358352', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358355', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358384', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358387', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358416', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358419', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358448', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358451', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358480', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358483', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358512', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358515', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358544', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358547', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_357971', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357459', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357203', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357075', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357011', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_356979', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_356976', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358096', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357555', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357296', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357139', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357072', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357040', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357008', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1091 | Q34 | What are the names of the genes that are targeted by the drug Apalutamide in the treatment of prostate cancer? | In the context of prostate cancer, the drug Apalutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate cancer%" OR LOWER(efo_term) LIKE "%prostate cancer%") AND (LOWER(drugName) LIKE "%apalutamide%" OR LOWER(tradeNames_list) LIKE "%apalutamide%" OR LOWER(syns_list) LIKE "%apalutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921863', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921873', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921876', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921882', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921886', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921892', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921893', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921902', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921903', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921906', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921912', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921916', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921922', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921923', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921926', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921932', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921933', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921936', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921942', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921943', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921946', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921953', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921956', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921962', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921963', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921952', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921872', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921856', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921852', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921846', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921896', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921913', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921883', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921866', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921862', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921853', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.486 | Q34 | What are the names of the genes that are targeted by the drug Lisdexamfetamine Dimesylate in the treatment of drug dependence? | In the context of drug dependence, the drug Lisdexamfetamine Dimesylate targets the gene solute carrier family 6 member 2, solute carrier family 18 member A2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%drug dependence%" OR LOWER(efo_term) LIKE "%drug dependence%") AND (LOWER(drugName) LIKE "%lisdexamfetamine dimesylate%" OR LOWER(tradeNames_list) LIKE "%lisdexamfetamine dimesylate%" OR LOWER(syns_list) LIKE "%lisdexamfetamine dimesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_419193', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419226', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419237', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419248', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419270', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419281', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419292', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419314', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419325', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419336', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419347', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419369', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419380', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419391', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419402', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419413', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419424', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419435', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419446', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419457', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419468', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419490', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419501', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419512', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419523', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419534', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419556', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419567', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419578', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419589', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419600', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419611', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419622', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419633', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419644', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419655', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419666', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419677', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419688', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419699', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419710', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419721', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419732', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419743', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419754', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419765', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419776', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419787', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419798', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419809', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419820', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419842', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419853', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419864', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419875', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419886', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419897', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419919', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419930', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419941', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419952', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419963', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419974', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419985', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419996', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420007', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420018', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420029', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420040', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420051', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420062', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420073', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420084', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420095', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420106', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420117', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420128', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420139', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420150', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420161', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420172', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420183', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420194', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420205', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420216', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420227', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419831', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419479', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419303', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419215', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419171', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419149', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419138', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419908', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419545', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419358', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419259', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419204', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419182', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419160', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.213 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218719', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219343', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219551', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219759', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220175', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220383', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220591', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220799', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219135', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218303', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217887', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217679', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219967', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218927', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218511', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218095', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.720 | Q34 | What are the names of the genes that are targeted by the drug Vemurafenib in the treatment of metastatic melanoma? | In the context of metastatic melanoma, the drug Vemurafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic melanoma%" OR LOWER(efo_term) LIKE "%metastatic melanoma%") AND (LOWER(drugName) LIKE "%vemurafenib%" OR LOWER(tradeNames_list) LIKE "%vemurafenib%" OR LOWER(syns_list) LIKE "%vemurafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752203', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752161', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752119', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752098', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752224', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752182', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752140', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.531 | Q34 | What are the names of the genes that are targeted by the drug Carbinoxamine Maleate in the treatment of urticaria? | In the context of urticaria, the drug Carbinoxamine Maleate targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urticaria%" OR LOWER(efo_term) LIKE "%urticaria%") AND (LOWER(drugName) LIKE "%carbinoxamine maleate%" OR LOWER(tradeNames_list) LIKE "%carbinoxamine maleate%" OR LOWER(syns_list) LIKE "%carbinoxamine maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455849', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urticaria', 'efo_term': 'urticaria', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455855', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urticaria', 'efo_term': 'urticaria', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.214 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218096', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217888', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218720', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219344', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219968', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219760', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220176', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217680', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218928', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219552', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220384', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220592', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218304', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220800', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219136', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218512', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218343', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219175', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219383', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218551', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219591', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219799', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220631', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217719', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218759', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220007', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220215', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217927', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217511', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218135', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220423', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218967', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.776 | Q34 | What are the names of the genes that are targeted by the drug Hydromorphone Hydrochloride in the treatment of drug dependence? | In the context of drug dependence, the drug Hydromorphone Hydrochloride targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%drug dependence%" OR LOWER(efo_term) LIKE "%drug dependence%") AND (LOWER(drugName) LIKE "%hydromorphone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%hydromorphone hydrochloride%" OR LOWER(syns_list) LIKE "%hydromorphone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_792050', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792077', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792086', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792068', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792014', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792005', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792032', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792059', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792041', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792023', 'drugName': 'Hydromorphone Hydrochloride', 'tradeNames_list': "['Dilaudid', 'Dilaudid-hp', 'Exalgo', 'Hydromorphone hydrochloridePalladone', 'Palladone-sr']", 'syns_list': "['Dihydromorphinone hydrochloride', 'Hydromorphone HCl', 'Hydromorphone hclHydromorphone hydrochloride', 'Hydromorphone hydrochloride ciiNSC-117862']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.326 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of myocarditis? | In the context of myocarditis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocarditis%" OR LOWER(efo_term) LIKE "%myocarditis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227782', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228637', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228922', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229207', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229777', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230062', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230347', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230917', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231202', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231487', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231772', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232342', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230632', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228352', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227212', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226642', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226357', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232057', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229492', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228067', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227497', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226927', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.844 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of stroke? | In the context of stroke, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833495', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833051', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832940', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833273', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833384', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833162', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.66 | Q34 | What are the names of the genes that are targeted by the drug Metoclopramide Hydrochloride in the treatment of gastroparesis? | In the context of gastroparesis, the drug Metoclopramide Hydrochloride targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 3A and 5-hydroxytryptamine receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastroparesis%" OR LOWER(efo_term) LIKE "%gastroparesis%") AND (LOWER(drugName) LIKE "%metoclopramide hydrochloride%" OR LOWER(tradeNames_list) LIKE "%metoclopramide hydrochloride%" OR LOWER(syns_list) LIKE "%metoclopramide hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199704', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroparesis', 'efo_term': 'gastroparesis', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199672', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroparesis', 'efo_term': 'gastroparesis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199664', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroparesis', 'efo_term': 'gastroparesis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199688', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroparesis', 'efo_term': 'gastroparesis', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199696', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroparesis', 'efo_term': 'gastroparesis', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199680', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroparesis', 'efo_term': 'gastroparesis', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.483 | Q34 | What are the names of the genes that are targeted by the drug Dextroamphetamine in the treatment of narcolepsy-cataplexy syndrome? | In the context of narcolepsy-cataplexy syndrome, the drug Dextroamphetamine targets the gene solute carrier family 6 member 2, solute carrier family 18 member A2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%narcolepsy-cataplexy syndrome%" OR LOWER(efo_term) LIKE "%narcolepsy-cataplexy syndrome%") AND (LOWER(drugName) LIKE "%dextroamphetamine%" OR LOWER(tradeNames_list) LIKE "%dextroamphetamine%" OR LOWER(syns_list) LIKE "%dextroamphetamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418427', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418466', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418479', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418492', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418518', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418531', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418544', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418570', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418583', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418596', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418609', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418635', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418648', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418661', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418674', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418687', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418700', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418713', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418726', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418739', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418752', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418778', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418791', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418804', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418817', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418830', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418856', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418869', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418882', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418895', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418908', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418921', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418934', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418947', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418960', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418973', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418986', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418999', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419012', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419025', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419038', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419051', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419064', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419077', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419090', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419103', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419116', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419129', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418765', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418557', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418453', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418401', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418375', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418362', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418843', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418622', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418505', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418440', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418414', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418388', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1168 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of melanoma? | Trametinib has not been approved by the FDA as a treatment for melanoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%melanoma%" OR LOWER(efo_term) LIKE "%melanoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927744', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927757', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927758', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927764', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927771', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927772', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927778', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927785', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927786', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927792', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927793', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927800', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927806', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927807', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927813', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927814', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927820', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927821', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927827', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927828', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927834', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927841', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927842', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927848', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927849', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927855', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927862', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927863', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927869', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927870', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927876', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927877', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927883', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927884', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927890', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927891', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927897', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927898', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927904', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927905', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927911', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927912', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927918', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927919', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927925', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927926', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927932', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927933', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927939', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927940', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927946', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927953', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927954', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927960', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927961', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927967', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927968', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927975', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927981', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927982', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927988', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927989', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927995', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927996', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928002', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928003', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928009', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928010', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928016', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928017', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928023', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928024', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928030', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928031', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928037', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928038', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928044', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928045', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928051', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928052', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928058', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928059', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928065', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928066', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928072', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928073', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927947', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927835', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927779', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927751', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927737', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927730', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927729', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927974', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927856', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927799', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927765', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927750', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927743', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927736', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1001 | Q34 | What are the names of the genes that are targeted by the drug Aclidinium Bromide in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Aclidinium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%aclidinium bromide%" OR LOWER(tradeNames_list) LIKE "%aclidinium bromide%" OR LOWER(syns_list) LIKE "%aclidinium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857457', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857439', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857445', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857463', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857451', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1104 | Q34 | What are the names of the genes that are targeted by the drug Darolutamide in the treatment of neoplasm? | In the context of neoplasm, the drug Darolutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%darolutamide%" OR LOWER(tradeNames_list) LIKE "%darolutamide%" OR LOWER(syns_list) LIKE "%darolutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924390', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924386', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924401', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924389', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924397', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924412', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924391', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924388', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924415', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924403', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924439', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924395', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924407', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924436', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924396', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924410', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924411', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924435', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924393', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924408', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924418', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924417', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924424', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924419', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924402', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924421', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924423', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924438', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924425', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924426', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924405', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924428', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924429', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924430', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924431', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924409', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924433', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924437', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924440', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924416', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924400', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924414', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924398', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924422', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924394', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924432', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924387', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924404', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924385', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924392', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924420', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924406', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924427', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924399', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924434', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924413', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1735 | Q34 | What are the names of the genes that are targeted by the drug Vutrisiran in the treatment of polyneuropathy? | In the context of polyneuropathy, the drug Vutrisiran targets the gene transthyretin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%polyneuropathy%" OR LOWER(efo_term) LIKE "%polyneuropathy%") AND (LOWER(drugName) LIKE "%vutrisiran%" OR LOWER(tradeNames_list) LIKE "%vutrisiran%" OR LOWER(syns_list) LIKE "%vutrisiran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097671', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097677', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097679', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097681', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097675', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097667', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097663', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097661', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097683', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097673', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097669', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097665', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'syns_list': "['ALN-65492', 'ALN-TTRSC02', 'Votrisiran', 'Vutrisiran']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.30 | Q34 | What are the names of the genes that are targeted by the drug Clozapine in the treatment of schizoaffective disorder? | In the context of schizoaffective disorder, the drug Clozapine targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizoaffective disorder%" OR LOWER(efo_term) LIKE "%schizoaffective disorder%") AND (LOWER(drugName) LIKE "%clozapine%" OR LOWER(tradeNames_list) LIKE "%clozapine%" OR LOWER(syns_list) LIKE "%clozapine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_157985', 'drugName': 'Clozapine', 'tradeNames_list': "['Clozapine', 'Clozaril', 'Fazaclo', 'Fazaclo odt', 'Versacloz', 'Zaponex']", 'syns_list': "['Clozapine', 'Clozapine (caraco)', 'Clozapine (clozaril)Clozapine (fazaclo)', 'Clozapine (ivax)', 'Clozapine (mylan)Clozapine (teva)', 'Clozapine (udl)', 'Clozapine (versacloz)Clozapine resolution mixture', 'HF 1854', 'HF-1854', 'Leponex', 'NSC-757429']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_157994', 'drugName': 'Clozapine', 'tradeNames_list': "['Clozapine', 'Clozaril', 'Fazaclo', 'Fazaclo odt', 'Versacloz', 'Zaponex']", 'syns_list': "['Clozapine', 'Clozapine (caraco)', 'Clozapine (clozaril)Clozapine (fazaclo)', 'Clozapine (ivax)', 'Clozapine (mylan)Clozapine (teva)', 'Clozapine (udl)', 'Clozapine (versacloz)Clozapine resolution mixture', 'HF 1854', 'HF-1854', 'Leponex', 'NSC-757429']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.622 | Q34 | What are the names of the genes that are targeted by the drug Nintedanib in the treatment of idiopathic pulmonary fibrosis? | In the context of idiopathic pulmonary fibrosis, the drug Nintedanib targets the gene kinase insert domain receptor, fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 2, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, platelet derived growth factor receptor alpha and fibroblast growth factor receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%idiopathic pulmonary fibrosis%" OR LOWER(efo_term) LIKE "%idiopathic pulmonary fibrosis%") AND (LOWER(drugName) LIKE "%nintedanib%" OR LOWER(tradeNames_list) LIKE "%nintedanib%" OR LOWER(syns_list) LIKE "%nintedanib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_678478', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678484', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678486', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678488', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678492', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678494', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678496', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678500', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678502', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678504', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678506', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678510', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678512', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678514', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678516', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678518', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678520', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678522', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678524', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678526', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678528', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678532', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678534', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678536', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678538', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678540', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678544', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678546', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678548', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678550', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678552', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678554', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678556', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678558', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678560', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678562', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678564', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678566', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678568', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678570', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678572', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678574', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678576', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678578', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678580', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678582', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678584', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678586', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678588', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678590', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678592', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678596', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678598', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678600', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678602', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678604', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678606', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678610', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678612', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678614', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678616', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678618', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678620', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678622', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678624', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678626', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678628', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678630', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678632', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678634', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678636', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678638', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678640', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678642', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678644', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678646', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678693', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678740', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678787', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678834', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678881', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678928', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678975', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_679022', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_679069', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_679116', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678594', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678530', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678498', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678482', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678474', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678470', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678468', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678608', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678542', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678508', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678490', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678480', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678476', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678472', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.344 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of choroiditis? | In the context of choroiditis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%choroiditis%" OR LOWER(efo_term) LIKE "%choroiditis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227800', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228655', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228940', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229225', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229795', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230080', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230365', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230935', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231220', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231505', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231790', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232360', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230650', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228370', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227230', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226660', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226375', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232075', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229510', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228085', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227515', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226945', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.855 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of Headache? | In the context of Headache, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%headache%" OR LOWER(efo_term) LIKE "%headache%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833954', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833797', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834425', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834896', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835367', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835210', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835524', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833640', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834582', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835053', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835681', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835838', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834111', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835995', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834739', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834268', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834149', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834777', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834934', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834306', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835091', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835248', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835876', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833678', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834463', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835405', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835562', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833835', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833521', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833992', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835719', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834620', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1844 | Q34 | What are the names of the genes that are targeted by the drug Simvastatin in the treatment of Hypercholesterolemia? | In the context of Hypercholesterolemia, the drug Simvastatin targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypercholesterolemia%" OR LOWER(efo_term) LIKE "%hypercholesterolemia%") AND (LOWER(drugName) LIKE "%simvastatin%" OR LOWER(tradeNames_list) LIKE "%simvastatin%" OR LOWER(syns_list) LIKE "%simvastatin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104005', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104109', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103901', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103797', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103791', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104103', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103999', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103895', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1974 | Q34 | What are the names of the genes that are targeted by the drug Topotecan Hydrochloride in the treatment of ovarian cancer? | In the context of ovarian cancer, the drug Topotecan Hydrochloride targets the gene DNA topoisomerase I mitochondrial. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ovarian cancer%" OR LOWER(efo_term) LIKE "%ovarian cancer%") AND (LOWER(drugName) LIKE "%topotecan hydrochloride%" OR LOWER(tradeNames_list) LIKE "%topotecan hydrochloride%" OR LOWER(syns_list) LIKE "%topotecan hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193578', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193577', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193650', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193649', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1368 | Q34 | What are the names of the genes that are targeted by the drug Acalabrutinib Maleate in the treatment of Mantle cell lymphoma? | In the context of Mantle cell lymphoma, the drug Acalabrutinib Maleate targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mantle cell lymphoma%" OR LOWER(efo_term) LIKE "%mantle cell lymphoma%") AND (LOWER(drugName) LIKE "%acalabrutinib maleate%" OR LOWER(tradeNames_list) LIKE "%acalabrutinib maleate%" OR LOWER(syns_list) LIKE "%acalabrutinib maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1024995', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025001', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025003', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025005', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025009', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025011', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025013', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025017', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025019', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025021', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025023', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025027', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025029', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025031', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025033', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025035', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025037', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025039', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025041', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025043', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025045', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025049', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025051', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025053', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025055', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025057', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025061', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025063', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025065', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025067', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025069', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025071', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025073', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025047', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025015', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024999', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024991', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024987', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024985', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025059', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025025', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025007', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024997', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024993', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024989', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1397 | Q34 | What are the names of the genes that are targeted by the drug Siponimod Fumarate in the treatment of relapsing-remitting multiple sclerosis? | In the context of relapsing-remitting multiple sclerosis, the drug Siponimod Fumarate targets the gene sphingosine-1-phosphate receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%relapsing-remitting multiple sclerosis%" OR LOWER(efo_term) LIKE "%relapsing-remitting multiple sclerosis%") AND (LOWER(drugName) LIKE "%siponimod fumarate%" OR LOWER(tradeNames_list) LIKE "%siponimod fumarate%" OR LOWER(syns_list) LIKE "%siponimod fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1036800', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036788', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036785', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036794', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036797', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036791', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.552 | Q34 | What are the names of the genes that are targeted by the drug Levocetirizine Dihydrochloride in the treatment of Rhinitis, Allergic, Perennial? | In the context of Rhinitis, Allergic, Perennial, the drug Levocetirizine Dihydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rhinitis, allergic, perennial%" OR LOWER(efo_term) LIKE "%rhinitis, allergic, perennial%") AND (LOWER(drugName) LIKE "%levocetirizine dihydrochloride%" OR LOWER(tradeNames_list) LIKE "%levocetirizine dihydrochloride%" OR LOWER(syns_list) LIKE "%levocetirizine dihydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455996', 'drugName': 'Levocetirizine Dihydrochloride', 'tradeNames_list': "['Levocetirizine dihydrochloride', 'Xusal', 'Xyzal', 'Xyzal allergy 24hrXyzall']", 'syns_list': "['Cetirizine (r)-form dihydrochloride', 'Cetirizine hydrochloride (r)-Levocetirizine dihydrochloride', 'Levocetirizine hydrochlorideLevocetirizine monohydrochloride', 'NSC-758898', 'UCB 28556', 'UCB-28556']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.454 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of allergic disease? | In the context of allergic disease, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic disease%" OR LOWER(efo_term) LIKE "%allergic disease%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361102', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361261', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361314', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361367', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361473', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361526', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361579', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361685', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361738', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361791', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361844', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361950', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362003', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362056', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362109', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362162', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362215', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362268', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362321', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362374', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362427', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362533', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362586', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362639', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362692', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362745', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362851', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362904', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362957', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363010', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363063', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363116', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363169', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363222', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363275', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363328', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363381', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363434', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363487', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363540', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363593', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363646', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363699', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363752', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363805', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363858', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363911', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363964', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364017', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364070', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364123', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364229', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364282', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364335', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364388', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364441', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364494', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364600', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364653', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364706', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364759', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364812', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364865', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364918', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364971', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365024', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365077', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365130', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365183', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365236', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365289', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365342', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365395', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365448', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365501', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365554', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365607', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365660', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365713', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365766', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365819', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365872', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365925', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365978', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366031', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366084', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364176', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362480', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361632', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361208', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360996', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360890', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360837', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364547', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362798', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361897', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361420', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361155', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361049', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360943', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.636 | Q34 | What are the names of the genes that are targeted by the drug Axitinib in the treatment of clear cell renal carcinoma? | In the context of clear cell renal carcinoma, the drug Axitinib targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1 and fms related receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%clear cell renal carcinoma%" OR LOWER(efo_term) LIKE "%clear cell renal carcinoma%") AND (LOWER(drugName) LIKE "%axitinib%" OR LOWER(tradeNames_list) LIKE "%axitinib%" OR LOWER(syns_list) LIKE "%axitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_689364', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689490', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689532', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689574', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689658', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689700', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689742', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689826', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689868', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689910', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689952', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690036', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690078', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690120', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689784', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689448', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689280', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689196', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689154', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689994', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689616', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689406', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689322', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689238', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.233 | Q34 | What are the names of the genes that are targeted by the drug Beclomethasone Dipropionate in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Beclomethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%beclomethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%beclomethasone dipropionate%" OR LOWER(syns_list) LIKE "%beclomethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_221043', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221112', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221135', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221158', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221204', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221227', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221250', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221296', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221319', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221342', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221365', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221411', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221434', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221457', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221480', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221503', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221526', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221549', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221572', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221595', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221618', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221664', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221687', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221710', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221733', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221756', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221802', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221825', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221641', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221273', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221089', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220997', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220951', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220928', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221779', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221388', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221181', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221066', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221020', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220974', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1234 | Q34 | What are the names of the genes that are targeted by the drug Metoprolol Succinate in the treatment of angina pectoris? | In the context of angina pectoris, the drug Metoprolol Succinate targets the gene adrenoceptor beta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%angina pectoris%" OR LOWER(efo_term) LIKE "%angina pectoris%") AND (LOWER(drugName) LIKE "%metoprolol succinate%" OR LOWER(tradeNames_list) LIKE "%metoprolol succinate%" OR LOWER(syns_list) LIKE "%metoprolol succinate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937658', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937680', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937636', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937614', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937603', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937669', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937647', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937625', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1523 | Q34 | What are the names of the genes that are targeted by the drug Nusinersen Sodium in the treatment of spinal muscular atrophy? | In the context of spinal muscular atrophy, the drug Nusinersen Sodium targets the gene survival of motor neuron 2, centromeric. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spinal muscular atrophy%" OR LOWER(efo_term) LIKE "%spinal muscular atrophy%") AND (LOWER(drugName) LIKE "%nusinersen sodium%" OR LOWER(tradeNames_list) LIKE "%nusinersen sodium%" OR LOWER(syns_list) LIKE "%nusinersen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072719', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072722', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072723', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072724', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072726', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072727', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072728', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072730', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072731', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072732', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072733', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072729', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072721', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072717', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072715', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072714', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072734', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072725', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072720', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072718', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072716', 'drugName': 'Nusinersen Sodium', 'tradeNames_list': "['Spinraza']", 'syns_list': "['Nusinersen sodium']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.898 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of frozen shoulder? | In the context of frozen shoulder, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%frozen shoulder%" OR LOWER(efo_term) LIKE "%frozen shoulder%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838135', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838186', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838203', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838220', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838254', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838271', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838288', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838305', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838169', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838101', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838067', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838050', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838237', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838152', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838118', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838084', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.368 | Q34 | What are the names of the genes that are targeted by the drug Halobetasol Propionate in the treatment of skin disease? | In the context of skin disease, the drug Halobetasol Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%skin disease%" OR LOWER(efo_term) LIKE "%skin disease%") AND (LOWER(drugName) LIKE "%halobetasol propionate%" OR LOWER(tradeNames_list) LIKE "%halobetasol propionate%" OR LOWER(syns_list) LIKE "%halobetasol propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_240740', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240724', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240720', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240732', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240736', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240728', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1243 | Q34 | What are the names of the genes that are targeted by the drug Maraviroc in the treatment of viral disease? | In the context of viral disease, the drug Maraviroc targets the gene C-C motif chemokine receptor 5. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%viral disease%" OR LOWER(efo_term) LIKE "%viral disease%") AND (LOWER(drugName) LIKE "%maraviroc%" OR LOWER(tradeNames_list) LIKE "%maraviroc%" OR LOWER(syns_list) LIKE "%maraviroc%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938390', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938453', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938474', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938495', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938537', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938558', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938579', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938432', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938348', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938306', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938285', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938516', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938411', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938369', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938327', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1537 | Q34 | What are the names of the genes that are targeted by the drug Dronabinol in the treatment of Nausea? | In the context of Nausea, the drug Dronabinol targets the gene cannabinoid receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nausea%" OR LOWER(efo_term) LIKE "%nausea%") AND (LOWER(drugName) LIKE "%dronabinol%" OR LOWER(tradeNames_list) LIKE "%dronabinol%" OR LOWER(syns_list) LIKE "%dronabinol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1073256', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073292', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073324', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073325', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073289', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073252', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073217', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073216', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073328', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073288', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073253', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073220', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.614 | Q34 | What are the names of the genes that are targeted by the drug Cabozantinib S-Malate in the treatment of renal cell carcinoma? | In the context of renal cell carcinoma, the drug Cabozantinib S-Malate targets the gene kinase insert domain receptor and MET proto-oncogene, receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal cell carcinoma%" OR LOWER(efo_term) LIKE "%renal cell carcinoma%") AND (LOWER(drugName) LIKE "%cabozantinib s-malate%" OR LOWER(tradeNames_list) LIKE "%cabozantinib s-malate%" OR LOWER(syns_list) LIKE "%cabozantinib s-malate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_669605', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669649', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669651', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669672', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669695', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669697', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669718', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669741', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669743', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669764', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669766', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669789', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669810', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669812', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669833', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669835', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669856', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669858', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669879', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669881', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669902', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669925', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669927', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669948', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669950', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669971', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669994', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669996', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670017', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670019', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670040', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670042', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670063', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670065', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670086', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670088', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670109', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670111', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670132', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670134', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670155', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670157', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670178', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670180', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670201', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670203', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670224', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670226', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670247', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670249', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670270', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670293', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670295', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670316', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670318', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670339', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670341', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670364', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670385', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670387', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670408', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670410', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670431', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670433', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670454', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670456', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670477', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670479', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670500', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670502', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670523', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670525', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670546', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670548', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670569', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670571', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670592', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670594', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670615', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670617', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670638', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670640', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670661', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670663', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670684', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670686', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670272', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669904', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669720', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669628', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669582', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669559', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669557', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670362', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669973', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669787', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669674', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669626', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669603', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669580', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1846 | Q34 | What are the names of the genes that are targeted by the drug Simvastatin in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Simvastatin targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%simvastatin%" OR LOWER(tradeNames_list) LIKE "%simvastatin%" OR LOWER(syns_list) LIKE "%simvastatin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104006', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104110', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103902', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103798', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103793', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104105', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104001', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103897', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.122 | Q34 | What are the names of the genes that are targeted by the drug Desvenlafaxine in the treatment of depressive disorder? | In the context of depressive disorder, the drug Desvenlafaxine targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%depressive disorder%" OR LOWER(efo_term) LIKE "%depressive disorder%") AND (LOWER(drugName) LIKE "%desvenlafaxine%" OR LOWER(tradeNames_list) LIKE "%desvenlafaxine%" OR LOWER(syns_list) LIKE "%desvenlafaxine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206622', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206607', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206664', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206638', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206625', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206626', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206627', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206631', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206619', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206608', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206732', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206670', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206674', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206768', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206614', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206644', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206645', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206646', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206649', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206650', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206651', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206655', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206656', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206657', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206632', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206661', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206610', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206781', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206634', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206637', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206669', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206782', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206621', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206760', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206639', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206802', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206679', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206643', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206681', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206682', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206685', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206686', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206687', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206688', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206691', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206692', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206693', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206694', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206697', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206698', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206699', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206703', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206704', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206705', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206706', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206709', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206710', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206712', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206658', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206718', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206719', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206662', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206725', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206726', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206663', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206795', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206733', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206667', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206739', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206740', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206668', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206746', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206747', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206789', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206753', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206754', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206673', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206788', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206761', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206675', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206767', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206803', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206676', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206774', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206775', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206810', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206809', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206796', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206680', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206700', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206652', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206628', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206616', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206711', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206633', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206613', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206640', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206615', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206620', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206609', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1334 | Q34 | What are the names of the genes that are targeted by the drug Maralixibat Chloride in the treatment of Alagille syndrome? | In the context of Alagille syndrome, the drug Maralixibat Chloride targets the gene solute carrier family 10 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%alagille syndrome%" OR LOWER(efo_term) LIKE "%alagille syndrome%") AND (LOWER(drugName) LIKE "%maralixibat chloride%" OR LOWER(tradeNames_list) LIKE "%maralixibat chloride%" OR LOWER(syns_list) LIKE "%maralixibat chloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_992697', 'drugName': 'Maralixibat Chloride', 'tradeNames_list': "['Livmarli']", 'syns_list': "['LUM-001', 'LUM001', 'Lopixibat chloride', 'Maralixibat chloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alagille Syndrome', 'efo_term': 'Alagille syndrome', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992701', 'drugName': 'Maralixibat Chloride', 'tradeNames_list': "['Livmarli']", 'syns_list': "['LUM-001', 'LUM001', 'Lopixibat chloride', 'Maralixibat chloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alagille Syndrome', 'efo_term': 'Alagille syndrome', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992705', 'drugName': 'Maralixibat Chloride', 'tradeNames_list': "['Livmarli']", 'syns_list': "['LUM-001', 'LUM001', 'Lopixibat chloride', 'Maralixibat chloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alagille Syndrome', 'efo_term': 'Alagille syndrome', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.596 | Q34 | What are the names of the genes that are targeted by the drug Lamotrigine in the treatment of bipolar disorder? | In the context of bipolar disorder, the drug Lamotrigine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar disorder%" OR LOWER(efo_term) LIKE "%bipolar disorder%") AND (LOWER(drugName) LIKE "%lamotrigine%" OR LOWER(tradeNames_list) LIKE "%lamotrigine%" OR LOWER(syns_list) LIKE "%lamotrigine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_653062', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653119', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653124', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653150', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653181', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653186', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653212', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653243', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653248', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653274', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653279', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653310', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653336', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653341', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653367', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653372', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653398', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653403', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653429', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653434', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653460', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653491', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653496', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653522', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653527', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653553', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653584', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653589', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653615', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653620', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653646', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653651', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653677', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653682', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653708', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653713', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653739', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653744', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653770', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653775', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653801', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653806', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653832', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653837', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653863', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653868', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653894', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653899', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653925', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653930', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653956', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653987', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653992', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654018', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654023', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654049', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654054', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654085', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654111', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654116', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654142', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654147', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654173', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654178', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654204', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654209', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654235', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654240', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654266', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654271', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654297', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654302', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654328', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654333', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654359', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654364', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654390', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654395', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654421', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654426', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654452', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654457', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654483', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654488', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654514', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654519', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_653961', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653465', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653217', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653093', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653031', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653000', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652995', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_654080', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653558', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653305', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653155', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653088', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653057', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653026', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1160 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of prostate cancer? | Trametinib has not been approved by the FDA as a treatment for prostate cancer, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate cancer%" OR LOWER(efo_term) LIKE "%prostate cancer%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928588', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928654', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928668', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928694', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928734', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928748', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928774', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928814', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928828', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928854', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928868', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928908', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928934', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928948', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928974', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928988', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929014', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929028', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929054', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929068', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929094', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929134', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929148', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929174', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929188', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929214', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929254', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929268', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929294', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929308', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929334', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929348', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929374', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929388', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929414', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929428', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929454', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929468', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929494', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929508', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929534', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929548', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929574', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929588', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929614', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929628', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929654', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929668', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929694', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929708', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929734', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929774', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929788', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929814', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929828', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929854', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929868', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929908', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929934', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929948', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929974', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929988', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930014', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930028', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930054', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930068', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930094', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930108', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930134', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930148', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930174', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930188', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930214', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930228', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930254', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930268', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930294', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930308', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930334', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930348', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930374', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930388', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930414', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930428', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930454', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930468', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929748', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929108', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928788', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928628', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928548', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928508', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928494', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929894', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929228', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928894', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928708', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928614', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928574', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928534', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.